The story of Sildenafil presents a challenging picture for shareholders. While the initial introduction generated substantial returns, the end of its exclusive rights opened the floodgates to cheaper competitors, https://thebookpage.com/story7126146/viagra-and-big-pharma-a-volatile-investment